Could cause temporary or reversible harm; serious harm is unlikely.
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
| Brand name | CINACALCET |
| Generic name | CINACALCET |
| Active ingredient(s) | CINACALCET HYDROCHLORIDE |
| Distributed by / for | Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059 |
| NDC | 69097-412-02 |
| Full product label | Cinacalcet Hydrochloride Tablets, 90 mg, 30-count bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga, India; Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-412-02 |
| Recalling firm | Cipla USA, Inc. |
| Distribution | USA Nationwide |
| Quantity | N/A |
| Recall initiated | 2026-06-29 |
| Report date | 2026-07-08 |
| Recall completed | — |
| Recall number | D-0676-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Warren NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗